Welcome to our dedicated page for Cerevel Therapeutics Holdings news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Holdings stock.
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). Formed in 2018 through a partnership between Bain Capital and Pfizer, Cerevel is headquartered in Cambridge, Massachusetts. The company is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases using a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity.
Cerevel's pipeline includes five clinical-stage investigational therapies and several preclinical compounds targeting a range of CNS disorders, such as Parkinson’s disease, Alzheimer’s disease psychosis, epilepsy, schizophrenia, and addiction. The company’s lead programs include:
- Emraclidine: An M4-selective positive allosteric modulator (PAM) in development for schizophrenia and Alzheimer’s disease psychosis.
- Darigabat: An α2/3/5-selective GABAA receptor PAM currently under development for epilepsy and panic disorder.
- Tavapadon: A D1/D5 partial agonist currently in Phase 3 for the treatment of Parkinson’s disease.
- CVL-871: A D1/D5 partial agonist in development for treatment of dementia-related apathy.
In recent news, Cerevel announced the pricing of its underwritten public offering, where it successfully raised approximately $450 million. Additionally, Cerevel reported positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon as an adjunctive therapy to levodopa in Parkinson’s disease. The company is also advancing its early clinical pipeline and discovery programs while exploring new modalities through internal research, external collaborations, or potential acquisitions.
On December 6, 2023, Cerevel announced its acquisition by AbbVie Inc. (NYSE: ABBV). The transaction, valued at approximately $8.7 billion, aims to bolster AbbVie’s neuroscience portfolio with Cerevel’s robust pipeline of therapies. The acquisition is expected to close by mid-2024, subject to regulatory approvals and other customary conditions.
Cerevel continues to drive forward with its mission, leveraging its deep understanding of neurocircuitry and targeted receptor subtype selectivity to develop innovative treatments for neuroscience diseases, ultimately aiming to improve patient outcomes and quality of life.
Cerevel Therapeutics (Nasdaq: CERE) announced that its chairperson and CEO Tony Coles will participate in a fireside chat during the Stifel Virtual 2023 CNS Days on March 29, 2023, at 10:30 am ET. The event will highlight the company's ongoing commitment to neuroscience diseases and its diversified pipeline, which includes five clinical-stage investigational therapies aimed at conditions like schizophrenia, Alzheimer’s disease psychosis, and epilepsy. A live webcast of the presentation will be available on the investor relations section of Cerevel's website, with a replay accessible afterward.
Cerevel Therapeutics (Nasdaq: CERE) announced that its chairperson and CEO, Tony Coles, M.D., will present at the 43rd Annual Cowen Health Care Conference. The presentation is scheduled for March 6, 2023, at 9:10 a.m. EST, and can be accessed via a live webcast on Cerevel's investor relations website. Cerevel is focused on neuroscience diseases, offering a diversified pipeline that includes five clinical-stage therapies targeting conditions like schizophrenia, Alzheimer's disease psychosis, epilepsy, panic disorder, and Parkinson's disease. A replay of the presentation will also be available on their website.
Cerevel Therapeutics (CERE) announced significant developments in its clinical pipeline and financial results for 2022. The company is currently enrolling participants in a Phase 1 trial for emraclidine targeted at Alzheimer’s disease psychosis, while its Phase 2 trials for schizophrenia are on track for data release in 1H 2024. As of December 31, 2022, Cerevel reported cash and equivalents of $950 million, projected to fund operations through 2025. Research and development expenses rose to $280.3 million, driven by ongoing clinical programs. Additionally, President Abraham Ceesay will depart on March 9, 2023.
Cerevel Therapeutics (Nasdaq: CERE) announced it will report its fourth quarter and full year 2022 financial results on February 22, 2023, prior to U.S. market open. A conference call will follow at 8:00 a.m. ET that same day. Investors can register for the call to receive dial-in details and access a live webcast on the company's website. Cerevel focuses on treating neuroscience diseases with a diversified pipeline of five clinical-stage therapies addressing conditions like Parkinson’s and epilepsy. The company emphasizes a targeted neurocircuitry approach and is engaged in ongoing R&D and potential collaborations.
Cerevel Therapeutics (Nasdaq: CERE) has announced the initiation of a Phase 1 trial for emraclidine, aimed at treating Alzheimer’s disease psychosis. Additionally, a Phase 2 trial for darigabat, targeting panic disorder, is set to begin in Q2 2023. The company is focused on expanding its neuroscience drug pipeline, addressing conditions like schizophrenia, epilepsy, and Parkinson's disease. Upcoming data readouts and a cash runway extending into 2025 position Cerevel to advance its novel therapies. A presentation at the J.P. Morgan Healthcare Conference is scheduled for January 10, 2023.
Cerevel Therapeutics (Nasdaq: CERE) has announced that CEO Tony Coles, M.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. The presentation is scheduled for 8:15 a.m. PST/11:15 a.m. EST, followed by a Q&A session with the executive team. Investors can access the live webcast on the company’s investor relations page, with a replay available later. Cerevel focuses on neuroscience diseases, with a diverse pipeline of investigational therapies targeting conditions like Parkinson’s, epilepsy, schizophrenia, and dementia-related apathy.
Cerevel Therapeutics announced positive results from a Phase 1 trial of emraclidine, a treatment for schizophrenia, indicating no significant increase in blood pressure. At week eight, the mean change in 24-hour ambulatory systolic blood pressure was -2.7 mmHg for the 10 mg dose and -0.4 mmHg for the 30 mg dose. The study confirmed that emraclidine does not cause a blood pressure increase exceeding 3 mmHg, aligning with FDA guidelines. The drug was well-tolerated, with a side effect profile consistent with earlier trials. A comprehensive Phase 2 program is set to read out in early 2024.
Cerevel Therapeutics announced promising results from its Phase 1b clinical trial of emraclidine, a selective muscarinic M4 receptor positive allosteric modulator aimed at treating schizophrenia. Findings showed statistically significant improvements in symptom severity after six weeks compared to placebo, with no major gastrointestinal side effects. The company is moving forward with its Phase 2 development program involving additional clinical trials expected to report in the first half of 2024, highlighting a potential breakthrough in schizophrenia treatment.
Cerevel Therapeutics (Nasdaq: CERE) announced participation in three key investor conferences focused on neuroscience. The events include the Guggenheim Healthcare Talks on November 15, Stifel 2022 Healthcare Conference on November 16, and the Evercore ISI HealthCONx Conference on November 29. Key executives, including Chief Medical Officer Raymond Sanchez and CEO Tony Coles, will lead engaging discussions. Live webcasts will be accessible via their investor relations webpage, with replays available post-event. Cerevel aims to advance treatments for neuroscience diseases.
Cerevel Therapeutics (CERE) has successfully completed a $599 million dual convertible debt and equity financing to enhance its neuroscience therapeutics pipeline. The company initiated the EMPOWER-3 trial for emraclidine in schizophrenia and received FDA Fast Track designation for the same drug in Alzheimer’s disease psychosis, with a Phase 1 trial expected by year-end 2022. As of September 30, 2022, Cerevel holds $1,030 million in cash and equivalents, expected to support operations into 2025.
FAQ
What is the current stock price of Cerevel Therapeutics Holdings (CERE)?
What is the market cap of Cerevel Therapeutics Holdings (CERE)?
What does Cerevel Therapeutics Holdings, Inc. specialize in?
When was Cerevel Therapeutics formed?
Where is Cerevel Therapeutics headquartered?
What are some of Cerevel Therapeutics' leading investigational therapies?
What is the significance of Cerevel’s recent Phase 3 TEMPO-3 trial results?
What recent financial achievement has Cerevel accomplished?
What major acquisition was announced involving Cerevel Therapeutics?
What is the expected closing date for the AbbVie acquisition of Cerevel?
What is Cerevel Therapeutics' approach to treating neuroscience diseases?
Who are the contacts for media and investor inquiries at Cerevel Therapeutics?
